Novartis acquires a small biotech and its trio of brain drugs

Cadent’s two other drugs, CAD-9303 and CAD-1883, have been respectively studied in schizophrenia and movement disorders.

2 Likes

CAD-9303, a novel, first-in-class, positive allosteric modulator (PAM) of N-methyl-D-aspartate (NMDA) receptors for the treatment of the cognitive deficits and negative symptoms of schizophrenia.

CAD-9303 is currently in Phase 1 studies in patients with Schizophrenia and plans to progress into a Phase 2 trial for treatment of Schizophrenia in the first half of 2021.

CAD-1883 is for a kind of ataxia.

2 Likes